Your session is about to expire
← Back to Search
Unknown
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) (REMOTE-HF Trial)
Phase 1
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing a new medicine called BAY2413555 to help people with chronic heart failure. The study will compare the safety and effects of BAY2413555 in patients who have special heart devices. Researchers hope this new medicine will protect the heart and improve its function.
Eligible Conditions
- Chronic Heart Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment arm 2Experimental Treatment2 Interventions
Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
Group II: Treatment arm 1Experimental Treatment1 Intervention
Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive placebo to BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
Find a Location
Who is running the clinical trial?
BayerLead Sponsor
2,277 Previous Clinical Trials
25,541,008 Total Patients Enrolled